The contractor shall provide preclinical development support for candidate products and drug development activities. The scope of work encompasses activities that range from initial product…

Active Awarded Last action

Contract number
75N93021D00007
Awardee
Awarding agency
Task orders
2 $18,397 obligated

Award facts

Opportunity
Combined order value
$18,397 Current and potential, with all options
Last date to order 86% complete
IDV ceiling <1% used
$107,274,471.00
Maximum order
$107,274,471.00
Award type
Multiple award
Who can order
Only the awarding agency
Set-aside
No set-aside
Competition
Full and Open Competition · 3 offers Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Legislative mandates

Award details come from SAM.gov/FPDS.

About this IDV

The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded multiple Indefinite Delivery/Indefinite Quantity contracts to provide preclinical development support for candidate products addressing HIV, HBV, HCV, and Mycobacterium tuberculosis. The total potential value of the IDV is $107,274,471 over seven years ending October 2027.

Task orders have been issued under several areas. Lovelace Biomedical Research Institute received a $18,397 order to develop quality plans under Task Area A for in vitro testing. Another order funded a $0 minimum amount for Lovelace under Task Area C for small animal HIV and HCV models in Albuquerque, NM. The original solicitation anticipated awarding contracts in seven task areas including in vitro and animal testing, synthesis of therapeutic agents with Task Area B set aside for small businesses, formulation development and manufacturing, pharmacology and toxicology services, and a reagent program. The purpose is to provide resources from discovery to clinical trials for candidate products emerging from investigator or partner-led research.

Description

The contractor shall provide preclinical development support for candidate products and drug development activities. The scope of work encompasses activities that range from initial product discovery to those required to support clinical trials and/o

Task orders

Transactions

Action Obligated Date
Vendor DUNS or Name Change - Non-Novation P00002 $0
Novation Agreement P00001 $0
Original award $0

Quick answers

Who was awarded contract 75N93021D00007?

75N93021D00007 was awarded to Lovelace Biomedical Research Institute by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on October 15, 2020.

How much is contract 75N93021D00007 worth?

Orders under 75N93021D00007 have obligated $18,397. 75N93021D00007's own ceiling is $107,274,471. A single order can be worth up to $107,274,471.

How many orders have been placed under contract 75N93021D00007?

2 orders have been placed under 75N93021D00007, the latest on April 15, 2021.

Who can order from contract 75N93021D00007?

75N93021D00007 is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.

Is contract 75N93021D00007 part of a contract vehicle?

Yes. 75N93021D00007 is part of Preclinical Services for HIV Therapeutics.

Was contract 75N93021D00007 competed?

The extent of competition for 75N93021D00007 was full and open competition. The government received 3 offers.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV